Source: CVR Medical Corp.
  • CVR Medical (CVM) has closed the first tranche of a non-brokered private placement for gross proceeds of $115,000
  • The first tranche consisted of 3,850,000 units priced at $0.03 per unit
  • The offering, a necessary step in relaunching operations under new leadership, may be closed in additional tranches
  • CVR Medical is a healthcare company that operates in the medical device industry focused on the commercialization of its proprietary CSS, a device designed to detect and measure carotid arterial stenosis
  • CVR Medical Corp. (CVM) is down 14.29 per cent on the day, trading at C$0.03 per share at 4 pm EST

CVR Medical (CVM) has closed the first tranche of a non-brokered private placement for gross proceeds of $115,000.

The first tranche consisted of 3,850,000 units priced at $0.03 per unit. Each unit consists of one common share and one transferable common share purchase warrant. Warrants are exercisable to acquire an additional common share for $0.12 per share.

The proceeds from the offering will be used to cover the costs of the Annual General Meeting and filings fees.

Completion of the offering is a necessary step in relaunching operations under new leadership, with the ultimate goal of commercializing the Carotid Stenotic Scan device.

The common shares and warrants will be subject to a hold period expiring April 24, 2022.

The offering may be closed in additional tranches.

CVR Medical Corp. is a healthcare company that operates in the medical device industry focused on the commercialization of its proprietary Carotid Stenotic Scan device (CSS). The CSS is a patented device designed to detect and measure carotid arterial stenosis.

CVR Medical Corp. (CVM) is down 14.29 per cent on the day, trading at C$0.03 per share at 4 pm EST.

More From The Market Online

PharmAla Biotech launches educational portal for MDMA

PharmAla Biotech (CSE:MDMA) launches its Prescribers Portal for medical practitioners to learn more about MDMA.

Cancer-fighting pharma stock eyes 2027 regulatory approval

Theralase Technologies (TSXV:TLT), a cancer-fighting pharma stock, expands its team with two clinical research associates.

PharmaDrug-PharmaTher Holdings JV submits clinical, regulatory package

Sairiyo Therapeutics, a PharmaDrug (CSE:PHRX) and PharmaTher Holdings (CSE:PHRM) joint venture, pursues a human clinical study in Australia.